BioInvent International
4.11.2021 14:27:04 CET | ACCESS Newswire | Press release
- BI-1206 restores rituximab activity in relapsed or refractory patients
- Demonstrates ORR 50%, DCR 58%, with complete responses lasting beyond 18 and 24 months
LUND, SE / ACCESSWIRE / November 4, 2021 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces additional positive interim top-line data from its novel anti-FcγRIIB antibody BI-1206. The data update comes from the company's Phase 1/2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) treating patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The latest data will be published in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) in December 2021.
BI-1206 in combination with rituximab demonstrated an objective response rate (ORR) of 50%, with three complete responses and three partial responses seen in twelve patients evaluated for therapeutic benefit. The treatment stabilized disease in one additional patient, giving a disease control rate of 58% (7 out of 12 patients). The complete responses also appear to be long-lasting, sustaining beyond 18 months and beyond 24 months in two patients completing the study. Previous rituximab treatments without BI-1206 had failed in these patients. The data were obtained from the dose-escalation phase of the trial up to July 2021 (the ASH abstract cut-off date). BI-1206 showed a good safety profile: infusion-related reactions can be managed with a steroid regimen.
"The current data are very encouraging and already show the benefit of BI-1206 in advanced NHL. Without BI-1206, single agent rituximab does not work well for this group of patients. These results suggest that BI-1206 not only restores the anti-tumor response but can do it in a prolonged manner in many patients. All this has been achieved with a dosing regimen for BI-1206 that may yet be further improved, and we look forward to continuing its clinical development with the aim of improving treatment options for these patients," said Martin Welschof, PhD, CEO of BioInvent.
Pharmacodynamic studies highlighted in the ASH 2021 abstract suggest that increasing the dosing of BI-1206 could lead to complete receptor saturation over an extended time, potentially leading to additional clinical benefits.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
Since October 2020, BioInvent has a licensing agreement in place with CASI Pharmaceuticals for China, including Hong Kong, Macau, and Taiwan. Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological and solid cancers, with CASI responsible for commercialization in China and associated markets.
ASH 2021 will take place on December 11-14, 2021, at the Georgia World Congress Center - Atlanta, GA, and virtually. BioInvent will present a poster entitled "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcγRIIB (CD32B), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab". The abstract is available online from November 4, 2021, at 9.00 am EDT (2 pm CET) and will be presented on December 11 at 5.30 pm ET (11:30 pm CET).
In mid-December, BioInvent will hold a live-streamed KOL event where the ASH poster data will be discussed. In addition, the first data from the Phase 1/2a study of BI-1206 in combination with Keytruda for the treatment of solid tumors will be reviewed.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-04 14:00 CET.
Attachments
BioInvent to show further positive BI-1206 clinical data in December at ASH 2021
SOURCE: BioInvent International AB
View source version on accesswire.com:
https://www.accesswire.com/671193/BioInvent-to-Show-Further-Positive-BI-1206-Clinical-Data-in-December-at-ASH-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo Omni SE, Omni Pro and Maxis Enter Final Week of Early Bird Launch Pricing24.7.2026 09:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / July 24, 2026 / Seven days is what remains of LiberNovo's 2026 launch pricing. Across the EU and UK, Omni SE, Omni Pro, and the Maxis series hold their early bird prices until July 31, and the window closes there. The whole lineup is built around dynamic ergonomics: the support system links the neck support, backrest, armrests, and seat, so everything moves together as you shift, lean, and recline. The chair follows the movement; you get on with the work. A quick way to choose Omni SE: the simplest build in the lineup. No motor and no battery; you set the lumbar depth by hand and the automatic support does the rest. Solid dynamic ergonomics at the friendlier price. Better Comfort, Simplified. Omni Pro: the premium chair in the lineup. Motorized lumbar adjustment and the OmniStretch guided back stretch at the press of a button, plus Active Airflow ventilation built into the seat for long days and warm rooms, an aluminum base, and Danish Gabriel fabric.
2026 Fields Medals Awarded to Four of World's Top Mathematicians23.7.2026 16:45:00 CEST | Press release
The award, nicknamed the Nobel Prize of mathematics, recognizes outstanding achievement - and the promise of future achievement - by mathematicians under 40. PHILADELPHIA, PA / ACCESS Newswire / July 23, 2026 / During today's opening ceremony at the International Congress of Mathematicians (ICM) in Philadelphia, the International Mathematical Union (IMU) announced the recipients of the 2026 Fields Medals. This year's prizes went to four of the world's top mathematicians: Chinese mathematician Yu Deng of the University of Chicago; American mathematician John Pardon of Stony Brook University in New York; Canadian mathematician Jacob Tsimerman of the University of Toronto; and Chinese mathematician Hong Wang of New York University and France's Institut des Hautes Études Scientifiques (IHES). The Fields Medal is often described as the Nobel Prize of mathematics due to its prestige. Awarded every four years to two to four mathematicians under the age of 40, the medal recognizes outstanding
Karbon-X Secures Technical Advisory Engagement for Nature-Based Carbon Project in Libya22.7.2026 15:00:00 CEST | Press release
Initial engagement expands the Company's international project development portfolio through technical advisory services supporting the design and optimization of a proposed nature-based carbon project. CALGARY, AB / ACCESS Newswire / July 22, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced that it has been engaged by Stream Pro Ltd, a subsidiary of Oilinvest to provide technical advisory services supporting the design and value optimization of a proposed nature-based carbon project in Libya. The engagement represents another step in Karbon-X's international project development strategy and further demonstrates the Company's expertise in the design and development of high-integrity carbon projects across emerging markets. Under the initial scope of work, Karbon-X will provide end-to-end technical support for the project's carbon design,
U.S. Polo Assn. Sponsors the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup as Official Apparel Partner22.7.2026 13:00:00 CEST | Press release
Gaston Polo Team Claims Gold Cup Title Over Dubai Polo Team at Cowdray Park Polo Club WEST PALM BEACH, FL AND WINDSOR, UK / ACCESS Newswire / July 22, 2026 / U.S. Polo Assn.® in partnership with Brand Machine Group (BMG), its partner in the United Kingdom, proudly continued its long-standing support of the British high-goal season as the Official Apparel Partner of the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup, held June 23 through July 19 at Cowdray Park Polo Club, known widely as "The Home of British Polo." 1) 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup Winners, Gaston Polo Team, accepting trophy on stage at Cowdray Park Polo Club 2) Gaston Polo Team attacking the ball against Dubai Polo Team in the 2026 St. Regis British Open Polo Championship for the Cowdray Gold Cup Final 3) The British Ladies Open Championship Finalists, Yaguara and Salty Polo, on stage at Cowdray Park Polo Club 4) U.S. Polo Assn.'s Experiential Merchandise
House of Hope in Bamako Continues to Provide Vital Support for Vulnerable Women in Mali in 202622.7.2026 11:00:00 CEST | Press release
BUDAPEST, HUNGARY / ACCESS Newswire / July 22, 2026 / The Gedeon Richter House of Hope centre in Bamako, Mali, continued to provide comprehensive support for vulnerable women and girls during the first half of 2026, delivering healthcare, protection, counselling, education and vocational training through its integrated programme. In the first six months of is year, nearly 50 women have been provided assistance in the center. Established through the cooperation of Gedeon Richter, the Hungary-based Close to Africa Foundation, and local partner Sini Sanuman Foundation, the House of Hope opened at the beginning of 2025 to offer shelter, gynaecological care, psychosocial and legal support, as well as educational and skills-development opportunities to women affected by violence and harmful traditional practices. Since opening its doors, the centre has supported well over a hundred women, while community outreach and awareness-raising activities have reached many more across Bamako and surro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom